Lobe Sciences (TSE:LOBE)
:LOBE
LOBE Stock Chart & Stats
C$0.06
-C$0.01(-33.33%)
At close: 4:00 PM EST
C$0.06
-C$0.01(-33.33%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.11
Previous CloseN/A
Volume8.00K
Average Volume (3M)19.65K
Market Cap
C$20.21M
Enterprise ValueC$8.79M
Total Cash (Recent Filing)C$7.02M
Total Debt (Recent Filing)C$295.68K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding269,487,120
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Small Debt LoadA very low debt burden and modest leverage materially reduce near-term refinancing and interest-rate pressure. For a development-stage biotech, limited debt preserves flexibility to fund R&D via equity or partnerships and lowers insolvency risk compared with highly leveraged peers.
Focused Therapeutic NicheConcentrated expertise in psychedelic-derived therapeutics targets a structurally growing market for mental-health innovation. A clear scientific niche can create differentiation, support specialized clinical programs, and attract strategic partners or grant funding over the medium term.
Recent Return To Positive EquityRestoring positive equity strengthens the company's solvency profile and improves access to capital markets or partners. This accounting improvement provides a buffer against operating losses and reduces short-term restructuring risk while development programs continue.
Bears Say
Near-Zero Revenue And Persistent LossesPractically no revenue and material operating losses indicate the business is not yet commercially scaled. Over the medium term this creates high funding dependency, weak internal cash generation, and uncertainty around translating clinical programs into sustainable revenue streams.
Ongoing Negative Operating Cash FlowSustained negative operating and free cash flow signal that core operations do not self-finance R&D or overhead. Without predictable cash generation, the company will likely need external financing or partnerships, which can dilute shareholders or constrain strategic choices.
Historic Equity Instability And Asset Expansion Via FinancingRapid asset growth driven by financing rather than operating cash flow points to dependence on capital raises or restructurings. This structural reliance raises execution and dilution risk, and questions sustainability if future funding channels tighten or clinical progress delays.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.02 and its highest was C$0.11 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$20.21M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is May 04, 2026 which is in 29 days.
How were Lobe Sciences’s earnings last quarter?
Currently, no data Available
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 269,487,120 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---